Apidra

Insulin Glulisine

Method of action: Drugs Used In Diabets, Hypoglycemic

Treatment option: Diabetes Mellitus

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Apidra

Quick Facts

Property	Description
Active ingredient	Insulin Glulisine
Form	Solution for injection (clear, colorless liquid)
Pharmacological class	Antidiabetic agent (Insulin)
Common use	Mealtime blood sugar control
Origin	Synthetic human insulin analog

What Type of Insulin is Apidra (Insulin Glulisine)?

Apidra is a prescription drug classified as a rapid-acting insulin analog, belonging to the high-level antidiabetic agent pharmacological class. The drug's active compound is Insulin Glulisine, which acts as a substitute for naturally produced insulin. This classification is clinically recognized for its ability to swiftly manage blood sugar spikes associated with food intake. The molecule’s rapid absorption and action profile allows the product to be administered shortly before or soon after starting a meal. This distinct speed reflects a design focused on providing optimal flexibility and optimized prandial control for the user.

Composition, Origin, and Available Form

The core of this medicine is Insulin Glulisine, a synthetic human insulin analog created through recombinant DNA technology. This advanced manufacturing process yields a consistent, high-quality single-ingredient product. Apidra is formulated as a sterile aqueous solution, which is a clear and colorless liquid for injection. It is supplied as a solution for injection in vials and in prefilled pen devices, providing options for traditional syringe administration or use in insulin pump systems. The Insulin Glulisine formulation has been specifically authorized for use across a wide patient group, including pediatric patients (children four years and older) with Type 1 diabetes, underscoring its broad utility.

General Purpose: Why is Apidra Used?

The overarching purpose of Apidra is to function as an exogenous insulin replacement used for immediate prandial control—the management of blood sugar levels coinciding with mealtimes. The rapid action of Insulin Glulisine helps to mitigate the sudden post-meal surges in blood glucose by accelerating the movement of sugar from the bloodstream into the cells. This targeted effect supports stable and effective overall glucose control, which is the general benefit derived from this blood glucose-lowering agent.

Regulatory References

APIDRA (insulin glulisine) Full Prescribing Information

What side effects are possible with Apidra?

Possible Side Effects and Safety Information

The most common adverse reaction documented for Apidra (Insulin Glulisine) is Hypoglycemia (low blood sugar), which is classified as Very Common (ge 1/10) in official regulatory documents. This is a characteristic safety profile element of all insulin therapies.

Other adverse reactions are primarily grouped under Skin and Subcutaneous Tissue Disorders and Immune System Disorders. Common (ge 1/100 to <1/10) effects include local hypersensitivity reactions and injection site reactions (e.g., pain, redness). Lipodystrophy and localized cutaneous amyloidosis are also documented, emphasizing the regulatory requirement for continuous rotation of the injection site.

Serious Adverse Reactions highlighted in regulatory labeling include Severe Hypoglycemia, which may result in loss of consciousness, and Systemic Hypersensitivity Reactions (e.g., anaphylaxis). Additionally, a documented risk of Hypokalemia exists, which can be life-threatening if untreated. The concomitant use of insulin with Thiazolidinediones (TZDs) carries a safety note regarding the potential for fluid retention and heart failure.

Specific safety considerations exist for special populations. In patients with Renal or Hepatic Impairment, insulin requirements may be reduced due to the body's slower metabolism of the medicine. Regulatory data also indicate that the risk of hypoglycemia may be higher in pediatric patients compared to adults. The official safety profile for Apidra is structured around the recognized high frequency of metabolic events and specific context-of-use constraints.

Overdose and Emergency Response

Overdose Manifestations

An overdose of Insulin Glulisine (Apidra) is officially defined by its primary physiological manifestation: hypoglycemia (low blood glucose). The initial, documented symptoms of an overdose often include sweating, shakiness, confusion, headache, fast heartbeat (palpitations), anxiety, and dizziness. These manifestations are directly linked to the metabolic and central nervous systems, which are sensitive to insufficient glucose supply. Regulatory information states that close monitoring of blood glucose is essential following an overdose event.

Severity and Mandated Emergency Action

Regulatory authorities recognize that severe hypoglycemia is a potentially life-threatening outcome of overdose. This condition may progress to serious manifestations such as loss of consciousness, seizures (convulsions), and carries the risk of permanent neurological impairment or death. For any suspected overdose, particularly if signs of severe hypoglycemia are present, immediate medical attention must be sought. Official regulatory guidance requires contacting emergency medical services or a poison control center without delay.

Treatment is symptomatic and supportive, centered on correcting the metabolic state. This may involve the administration of oral glucose or, for severe cases, intravenous glucose or glucagon. This protocol is necessary because no specific antidote is known for insulin. Extended hospital observation may be required to prevent a relapse of hypoglycemia.

Therapeutic Uses of Apidra

Quick Facts: What Apidra is Used For

Support for Glucose Management: May be incorporated into a regimen to support appropriate blood sugar levels.
Patient Population: Used in adults and children with diabetes mellitus who require insulin therapy.
Therapeutic Goal: Intended to contribute to improved glycemic control in conjunction with other components of a diabetes treatment plan.

What Apidra Treats: Main Uses and Benefits

Apidra (insulin glulisine) is a treatment option indicated for use in adult and pediatric patients with diabetes mellitus. The primary role of this medication is to improve glycemic control, a term used to describe the management of blood glucose (sugar) concentrations.

Its therapeutic contribution helps to address the body's need for insulin, which is essential for transporting glucose from the bloodstream into the body's cells for energy. When used as part of a complete management plan that typically includes an intermediate- or long-acting insulin, Apidra assists in the regulation of blood sugar levels around meal times.

This medication is a component of a comprehensive treatment strategy designed to support the patient's overall health and is utilized to manage the high blood sugar concentrations associated with the condition. The goal of this treatment approach is to aid in maintaining suitable blood glucose targets.

Eligibility and Restrictions for Use

Who Can and Cannot Use Apidra?

The official regulatory documents define strict criteria for Apidra (insulin glulisine) eligibility, focusing on age, contraindications, and specific medical conditions.

Category	Official Regulatory Statement
Populations for whom use is allowed	Approved for adults with diabetes mellitus (Type 1 and Type 2) and pediatric patients.
Populations for whom use is contraindicated	Must NOT be used during episodes of hypoglycemia (low blood sugar) or in patients with known hypersensitivity to insulin glulisine or its excipients.
Age-related eligibility rules	Use is established for children 4 years of age with Type 1 diabetes (US label) or 6 years of age (EU label). Safety and efficacy are not established in children under four or in children with Type 2 diabetes.
Condition-specific eligibility rules	Use requires caution in patients with Renal or Hepatic Impairment, as insulin requirements may be diminished due to altered drug clearance.
Pregnancy and lactation eligibility status	Use during pregnancy is permitted only if the benefit justifies the risk. Use during lactation (breastfeeding) is generally acceptable, though dose adjustments may be required.

Connection to the Overall Eligibility Profile Regulatory documents establish absolute prohibitions (hypoglycemia and hypersensitivity) that strictly exclude certain patient populations. The profile also clearly restricts use in specific pediatric age groups where safety is "not established," and requires special consideration for patients with reduced liver or kidney function.

What should I know about interactions with other medicines?

Apidra Interactions with Other Medicines and Products

This section describes interactions for Apidra (Insulin Glulisine) that are formally documented in government regulatory sources, based on effects on glucose metabolism or formulation restrictions.

Substances Affecting Blood Glucose Levels

Many medicines are officially documented to affect the efficacy of Apidra by either increasing or reducing its glucose-lowering effect:

Substances that May Increase the Effect (Risk of Hypoglycemia): This large group includes other antidiabetic agents, salicylates, ACE inhibitors, MAOIs, fibrates, disopyramide, and sulfonamide antibiotics.
Substances that May Reduce the Effect (Risk of Hyperglycemia): This group includes corticosteroids, thyroid hormones, diuretics, somatropin (growth hormone), danazol, estrogens and progestogens (e.g., in oral contraceptives), and sympathomimetic agents.

Antiadrenergic drugs, such as beta-blockers, clonidine, guanethidine, and reserpine, may officially mask or reduce the signs of hypoglycemia when used concomitantly.

Restrictions and Specific Cautions

Classification	Official Regulatory Constraint
Mixing Prohibition	Apidra must not be mixed with any insulin other than NPH human insulin for subcutaneous injection. It must not be mixed with diluents or any other insulin for pump use.
Combination Risk	Co-administration with Thiazolidinediones (TZDs) carries a labeled risk of fluid retention and heart failure.
Alcohol	Ethanol (alcohol) is explicitly documented to either increase or decrease the blood glucose-lowering activity.
Timing Condition	If mixed with NPH human insulin, Apidra must be drawn into the syringe first and injected immediately after mixing.

Population-Specific Notes

The effects of Apidra may be increased in patients with renal (kidney) or hepatic (liver) impairment due to a reduced rate of clearance from the body, as cited in regulatory information. Official documents state that studies on pharmacokinetic interactions have not been performed, and clinically relevant enzyme- or transporter-mediated interactions are considered unlikely to occur.

Mechanism of Action

Apidra is the brand name for insulin glulisine, an insulin analog with a modified structure designed for rapid action. Upon subcutaneous injection, the amino acid substitutions at positions B3 and B29 accelerate the dissociation of the hexameric form into active monomers. These monomers rapidly bind to the insulin receptors (IRs) expressed on the membranes of target cells, primarily skeletal muscle and adipose tissue.

This binding acts as an agonist, activating the intrinsic tyrosine kinase domain of the receptor. The resulting autophosphorylation initiates an intracellular signaling cascade via the PI3K/AKT pathway. A critical downstream effect is the translocation of GLUT4 glucose transporters to the cell surface, enhancing the rate of glucose transport from the circulation into peripheral cells. Concurrently, Apidra modulates hepatic enzymes to inhibit gluconeogenesis and glycogenolysis, which collectively results in a net system-level reduction of plasma glucose concentration.

Dosage and Administration Information

Administration Guidelines for Apidra (Insulin Glulisine)

Route and Timing of Administration

Apidra is administered by subcutaneous injection (SC), continuous subcutaneous infusion (CSII) via an external pump, or intravenously (IV). For SC injection, the insulin must be given within 15 minutes before a meal or within 20 minutes after starting a meal. The SC injection sites—the abdominal wall, thigh, or upper arm—must be rotated from one injection to the next within the same region to reduce the risk of localized skin changes.

Dosing and Preparation

The dosage must be individualized based on the patient's metabolic needs and continuous blood glucose monitoring. Apidra administered by SC injection should generally be used in a regimen that also includes an intermediate or long-acting insulin.

Inspection: Before use, the solution must be visually inspected and must appear clear and colorless with no particulate matter.
Mixing (SC): For subcutaneous injection, Apidra should not be mixed with insulins other than NPH human insulin. If mixing with NPH insulin, Apidra must be drawn into the syringe first and injected immediately after mixing.
CSII (Pump) Use: When used in a pump, Apidra must not be mixed or diluted with any other insulin or diluent. The Apidra in the reservoir and the infusion set should be changed at least every 48 hours.
IV Use: Intravenous administration must be performed only under strict medical supervision and requires the insulin to be diluted in 0.9% sodium chloride injection.

The SoloStar prefilled pen, intended for a single patient, delivers the dose in 1-unit increments. The safety and efficacy of Apidra in children less than 4 years of age with Type 1 diabetes or in children with Type 2 diabetes has not been established.

Recent Clinical Evidence

Research evidence / Overview of studies

Overview of Clinical Research

Research has explored whether insulin glulisine may influence inflammation pathways. Studies examined how the drug may work, and evaluated outcomes regarding common symptoms. The initial focus of research was evaluating whether the drug was associated with short-term changes in a specific biomarker.

Studies evaluated whether a combination of this drug and other agents was associated with different patient outcomes compared to comparator treatments alone. The primary trials for this drug were typically randomized, double-blind, and placebo-controlled or active-controlled trials, often comparing it to regular human insulin or insulin lispro.

Key Efficacy Findings

A meta-analysis analyzed data regarding recurrence risk in individuals receiving the drug. The analysis reported data on recurrence rates and drug usage. Findings from initial trials, involving adults and children (aged 6 and older) with Type 1 or Type 2 diabetes, included data on specific symptom scores at the 4-week and 12-week marks, with the main measure of effectiveness being the change in HbA1c levels.

Studies evaluating patients taking the drug for six months included patient-reported outcomes on symptom changes and tolerability measures. Researchers examined various dosing regimens and their correlation with changes in lab measures.

Safety and Tolerability Profiles

Clinical trials documented adverse event rates in various patient groups. Research has examined the use of this drug in individuals with pre-existing kidney or hepatic conditions. Common adverse events documented in placebo-controlled studies included headache and fatigue.

Furthermore, studies evaluating long-term usage examined whether the drug was associated with a lower need for follow-up interventions. Studies evaluating how the drug is absorbed examined taking it with or without food.

Frequently Asked Questions (FAQ)

Common questions about Apidra (FAQ)

Q: How quickly does Apidra start working after an injection?

According to official product information, Apidra is classified as a rapid-acting insulin. The onset of action, or the time it takes for the medicine to start working after a subcutaneous injection, is approximately 15 minutes. This quick action is why Apidra is typically administered around mealtimes for blood sugar management.

Q: How long does the effect of Apidra typically last?

Pharmacological studies cited in regulatory documents indicate that the duration of action for Apidra, following a subcutaneous injection, typically lasts between 2 to 4 hours. This relatively short duration aligns with its purpose as a mealtime, or prandial, insulin.

Q: Does Apidra cause weight gain?

Weight gain is listed in regulatory documents as a common adverse reaction associated with the use of Apidra. Official product information indicates that patients who experience concerns about changes in their body weight should consult their healthcare professional.

Q: What are the symptoms of low blood sugar that may happen with Apidra?

Low blood sugar, or hypoglycemia, is the most common side effect of Apidra. Official patient counseling information lists potential signs and symptoms, which may include sweating, confusion, dizziness or light-headedness, headache, blurred vision, shakiness, fast heartbeat, and hunger.

Q: Can stress or illness change how Apidra affects me?

Official dosing and administration instructions state that insulin requirements may be altered during times of significant stress or major illness. These external factors can change how your body processes glucose and how much insulin it needs.

Q: Does Apidra interact with common over-the-counter pain relievers?

Regulatory documents list salicylates as a substance that may potentially increase the blood glucose-lowering effect of insulin. Salicylates are included in certain over-the-counter pain relievers, and this interaction may increase the risk of low blood sugar.

Q: Are there specific foods or drinks that affect how Apidra works?

Official drug interaction information explicitly documents that alcohol (ethanol) may affect blood sugar levels. Alcohol intake is described to either increase or decrease the glucose-lowering activity of Apidra.

Q: What kind of monitoring is typically required while using Apidra?

Continuous blood glucose monitoring is indicated for all patients. When Apidra is administered intravenously, close monitoring of blood glucose and serum potassium is described in official documents. Monitoring for signs of fluid retention and heart failure is also noted when Apidra is used alongside Thiazolidinediones (TZDs).

Q: How does Apidra compare to insulin lispro in terms of action time?

Apidra and insulin lispro are both classified as rapid-acting insulin analogs. Clinical studies have demonstrated that Apidra's rapid onset and short duration of action are generally considered similar to that of insulin lispro when compared against regular human insulin.

Q: How does the onset of action of Apidra compare to Novolog (insulin aspart)?

Apidra (insulin glulisine) and NovoLog (insulin aspart) are both categorized as rapid-acting insulin analogs. Both medicines have similar pharmacological properties, including a rapid onset and short duration of activity, allowing them to be used for prandial (mealtime) control.

Q: Are there any long-term side effects associated with Apidra use?

Official labeling documents adverse events linked to long-term injection, specifically the chronic skin changes lipodystrophy (skin thickening or pitting) and localized cutaneous amyloidosis. These risks highlight why continuous rotation of the injection site is described in regulatory guidelines as a method to help reduce these risks.

Q: Is Apidra used to treat diabetic ketoacidosis (DKA)?

Apidra can be administered intravenously (IV) for glycemic control in a hospital setting. Official product information indicates that this administration method is required to be performed only under strict medical supervision with close patient monitoring.

Q: Do official sources describe any vision changes linked to Apidra?

Official documents list blurred vision as a potential sign or symptom of hypoglycemia, which is the most common side effect of Apidra. This occurs when blood sugar drops too low.

Q: Is it normal to feel a sting when injecting Apidra?

Injection site reactions are listed as common side effects in clinical trials. These reactions are described to include pain at the injection site, as well as redness or swelling.

Q: Are there any specific lifestyle changes recommended when starting Apidra?

The official product information states that Apidra is intended to be used as part of a complete diabetes treatment program. This comprehensive program typically includes factors like careful attention to diet and an exercise regimen, which help support overall glucose control.

How should Apidra be stored and disposed of?

How to Store and Dispose of Apidra?

Strict storage conditions are required to maintain the stability of Apidra (Insulin Glulisine). Unopened pens and vials must be kept in a refrigerator between 2 C and 8 C and stored in the original carton to protect the solution from light. The product must never be frozen; discard immediately if freezing has occurred.

Once the product is in-use (opened), it must not be refrigerated and should be stored at room temperature (typically below 25 C). The in-use shelf-life is strictly limited: the pen or vial must be discarded after 28 days from the first use, regardless of the remaining volume.

For safety, Apidra must be stored out of the sight and reach of children. All used needles must be placed in a designated puncture-proof sharps container. Unused or expired medication should be returned to a pharmacist or disposed of according to local authority regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.